🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,413 results for “ACE” Clear

  1. Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Placebo to match LY3298176 injection

    Eli Lilly Co.

    Obesity

    phase 3 small molecule active

    1 trial

  2. Tocilizumab, Placebo to match 2 mg/mL oral suspension, BARICITINIB, Baricitinib, Placebo to match 4 mg tablet, TOCILIZUMAB , Placebo to match 2 mg tablet, JAK1/JAK2 inhibitor, Placebo to match 1 mg tablet, BARICITINIB

    Eli Lilly Co.

    Systemic Juvenile Idiopathic Arthritis

    phase 3 small molecule active

    1 trial

  3. Tofersen

    IONIS PHARMACEUTICALS INC

    ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation

    phase 3 small molecule completed

    1 trial

  4. Tofersen

    IONIS PHARMACEUTICALS INC

    Amyotrophic Lateral Sclerosis

    phase 3 small molecule completed

    1 trial

  5. Tora-Dol 30 mg/ml soluzione iniettabile, Acido Acetilsalicilico Teva Italia 100 mg compresse gastroresistenti, SODIO CLORURO 0,9% BAXTER Soluzione per infusione

    Fondazione Telethon ETS

    Patients scheduled for major surgery for oncologic indication

    phase 3 small molecule active

    1 trial

  6. Tozorakimab, -, SALBUTAMOL, Tozorakimab-placebo

    AstraZeneca AB

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule active

    1 trial

  7. Tozorakimab, Tozorakimab-placebo

    AstraZeneca AB

    Severe viral lung infections

    phase 3 small molecule active

    1 trial

  8. Tozorakimab-placebo, Tozorakimab, SALBUTAMOL

    AstraZeneca AB

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule active

    1 trial

  9. Trabectedin

    Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    Ovarian Cancer

    phase 3 small molecule completed

    1 trial

  10. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Coronavirus Infection

    phase 3 small molecule active

    1 trial

  11. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Idiopathic Gastroparesis

    phase 3 small molecule active

    2 trials

  12. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Nausea and Vomiting

    phase 3 small molecule active

    1 trial

  13. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Atopic Dermatitis

    phase 3 small molecule completed

    3 trials

  14. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Motion Sickness

    phase 3 small molecule active

    4 trials

  15. Tranexamic Acid

    Arrowhead Pharmaceuticals Ireland Limited

    Hemorrhagic Shock

    phase 3 small molecule completed

    1 trial

  16. Transcranial Magnetic stimulation

    CNS Pharmaceuticals

    Gambling Disorder

    phase 3 other active

    1 trial

  17. Trazimera 420 mg powder for concentrate for solution for infusion, Perjeta 420 mg concentrate for solution for infusion, VINORELBINE ARROW 10 mg/ml, solution à diluer pour perfusion, TherO2-01S22, PACLITAXEL AHCL 6 mg/ml, solution à diluer pour perfusion, Placebo syrup, Docetaxel Accord 160 mg/8 ml concentrate for solution for infusion

    Ningbo Cancer Hospital

    metastatic breast cancer

    phase 3 small molecule active

    1 trial

  18. Treprostinil, The Placebo Nebuliser Solution is a solution dosage form for nebulisation identical to Treprostinil Nebuliser Solution drug product except for the absence of the treprostinil drug substance.

    United Therapeutics Europe Ltd

    Progressive Pulmonary Fibrosis

    phase 3 small molecule active

    1 trial

  19. Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension, SALBUTAMOL, Placebo MDI HFA to match BGF MDI HFA, Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension

    AstraZeneca AB

    Moderate to Severe Chronic Obstructive Pulmonary Disease(COPD)

    phase 3 small molecule active

    1 trial

  20. Trofinetide

    Acadia Pharmaceuticals B.V.

    Rett Syndrome

    phase 3 small molecule completed

    4 trials

  21. Troriluzole, Placebo for BHV-4157 capsules, 100mg, 140mg, Troriluzole

    Lacuna Pharma Pty Ltd

    Obsessive Compulsive Disorder

    phase 3 small molecule active

    1 trial

  22. UI022 or UI023 and co-administration of matching placebo

    United Therapeutics Europe Ltd

    Peripheral Arterial Disease

    phase 3 small molecule completed

    1 trial

  23. Ultomiris 1,100 mg/11 mL concentrate for solution for infusion, Anti C5 Complement mAb Placebo

    Alexion Europe SAS

    Delayed Graft Function after Kidney Transplantation

    phase 3 small molecule active

    1 trial

  24. Upadacitinib Placebo, Upadacitinib

    AbbVie Deutschland GmbH & Co. KG

    non-segmental vitiligo

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources